A refined use of mutations to guide immunotherapy decisions.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Genomic signature driving preinvasive to invasive processes in stage I lung adenocarcinoma.International journal of cancer · 2026
   Article
2. Integrative Analysis Reveals the Prognostic Effects of Epigenetic Regulators in Bladder Cancer.Cancer medicine · 2025
   Article
3. The Mutual Regulatory Role of Ferroptosis and Immunotherapy in Anti-tumor Therapy.Apoptosis : an international journal on programmed cell death · 2024
   Review
4. Somatic mutations of esophageal adenocarcinoma: a comparison between Black and White patients.Scientific reports · 2024
   Article
5. Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer:Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
   Article

Corrections and comments

• Comment on
  Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.2022

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as